niagenbioscience.com (NAGE) - Total Stockholders' Equity

NAGE (ChromaDex Corporation) - company brandmark

This daily price chart for Chromadex Corp (NAGE) is recorded at 0.08. Chromadex Corp dominates the creation of patented components for cell metabolism, protecting itself from cheap imitations through intellectual property rights. Revenues are based on the production of biochemical supplements, where Niagen for dietary supplements serves as the key driver. Supply chain stability is ensured by streamlined industrial transportation of chemical raw materials to the plants.

NAGE Chromadex Corp Book Capitalization (03/20/2025 - 10/28/2026)

Chromadex Corp (NAGE) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Rate Chart Niagen|NAGE - Analyst Consensus Forecast
- market capitalization data:
Market Value ChromaDex Corp|NAGE - Total Company Value
- book capitalization data:
Accounting Value per Share ChromaDex|NAGE - Book Capitalization|Market-to-Book Ratio niagenbioscience.com|NAGE - Company Total Assets
- debt and liquidity data:
Debt to Equity Ratio Chromadex Corp|NAGE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient niagenbioscience.com|NAGE - Company Aggregate Debts|Debt to Book Value ChromaDex Corp
Fundamental valuation:NAGE - ChromaDex Corp.
Mass-produced product of niagenbioscience.com

Book value reflects the actual value of the issuer's net assets minus all liabilities, determining the business's internal margin of safety. Analyzing the book value of Chromadex Corp (NAGE) allows for an assessment of the actual protection of investments against default. The metric is calculated as the difference between total assets and debts. For Chromadex Corp (NAGE), growth in this indicator confirms the effectiveness of its patent monopoly on Nicotinamide Riboside. Stable capital accumulation solidifies the company's dominance in the B2B sector of anti-aging biotechnology.

Competitor analysis for Chromadex Corp

ISRG - Book Value of Business|Book Capitalization DHR|BDX (bd.com) - Total Stockholders' Equity|Company Book Value STE|Company Net Assets West Pharma|Baxter Corp - Book Capitalization|Total Stockholders' Equity Masimo Inc. (MASI)|STVN - Book Capitalization|Accounting Capitalization teleflex.com TFX|Book Capitalization MMSI (Merit Medical)|NVST - Book Valuation of Business|ICUI (ICU Medical Corp) - Book Capitalization|Sirona Dental Systems (XRAY) - Company Net Assets|LMAT (LeMaitre Vascular, Inc.) - Book Capitalization|Book Capitalization ATRC|Company Book Value STAAR Surgical (STAA)|Company Book Value ZimVie Inc ZIMV|Company Net Assets AngioDynamics Corp|Accounting Value of Company Cerus Inc CERS|Book Capitalization TKNO (Alpha Teknova, Inc.)|MGRM: Book Valuation of Business|Company Book Value sharpstechnology.com|INFU (InfuSystem Holdings, Inc.) - Accounting Capitalization|UTMD: Company Book Value|Book Valuation of Business KORU Medical Systems Inc. (KRMD)|Company Net Assets Nyxoah S.A.|Total Net Assets MBOT (microbotmedical.com)|Company Book Value Pro-Dex|ZTEK - Accounting Value of Company|Elutia Corp - Company Net Assets|MLSS: Book Capitalization|NXGL (NEXGEL, Inc.) - Company Book Value|Retractable Technologies, Inc. (RVP) - Company Net Assets|Book Capitalization HBIO (Harvard Bioscience, Inc.)|Total Stockholders' Equity FEMY|Company Book Value MeihuaMed MHUA|Accounting Capitalization predictive-oncology.com POAI|Company Net Assets Callan JMB (CJMB)|atrioncorp.com - Total Net Assets|Company Book Value NURO (NeuroMetrix)